Helicobacter pylori, a class 1 carcinogen colonizes stomach causing gastric carcinoma. Rising antibiotic resistance and reinfections are drawbacks of antibiotic therapies. Alternating drugs and vaccination may be the promising approach to prevent and treat reoccurring infections. Therefore, there is a need for discovery of drug targets, drugs and vaccine candidates for the treatment of H. pylori. An objective of this current study is to identify potential drug targets and suitable vaccine candidates for H. pylori strain Hp26695 by insilico genome and proteome analysis. Drug targets were identified initially by comparing the genomes between H. pylori and Homosapien sapiens using RAST. RAST identified a total of 569 unique genes. These unique genes later were subjected to non-homology and gene property analysis to identify the potential drug targets. BLASTpfollowed by gene property analysis of 569 unique genes identified seven potential drug targets. Vaccine candidates were identified initially by screening protein sequences for pathogenic factors. These pathogenic factors were screened to identify non-homologous molecules and secondary structure patterns (helices). The proteins ≤ 3 helices are subjected to screening of antigenic nature followed by allergenicity. The proteins qualifying the above criteria were screened for antigens, Bcells and T-cell epitopes. Proteins showing positive predictions for antigenic, B-cell, T-cell activities are thus shortlisted as vaccine candidates for vaccine designing. Analysis identified 16 immunogenic proteins contributing to immune-response. These methods have enabled rapid identification of potential drug targets and vaccine candidates for strain Hp26695 with possible therapeutic implications for gastric cancer. cancer.
